Latest From Mirum Pharmaceuticals
Newly public Mirum hopes to file maralixibat for US approval in pruritus due to Alagille syndrome based on Phase IIb data, including long-term extension data reported at AASLD.
The latest drug development news and highlights from our US FDA Performance Tracker.
Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- North America
- Company Type
- Parent & Subsidiaries
- Mirum Pharmaceuticals
- Senior Management
Chris Peetz, Pres. & CEO
Pamela Vig, PhD, CSO
Lara Longpre, Chief Development Officer
Ian Clements, PhD, SVP, Fin. & Communications
Ed Tucker, CMO
- Contact Info
Phone: (650) 667-4085
950 Tower Ln.
Foster City, CA 94404
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.